Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure

被引：1

作者：

Arici M.K. ^{[1
,2
]}

Topalkara A. ^{[1
]}

Güler C. ^{[1
]}

机构：

[1] Department of Ophthalmology, Cumhuriyet University, School of Medicine, Sivas

[2] Cumhuriyet Universitesi Tip F., Göz ABD

来源：

International Ophthalmology | 1998年 / 22卷 / 1期

关键词：

Additive effect; Dorzolamide; Intraocular pressure; Latanoprost;

D O I：

10.1023/A:1006176713983

中图分类号：

学科分类号：

摘要：

Purpose: To evaluate the additive ocular hypotensive effect of latanoprost and dorzolamide in combination, on intraocular pressure reduction in patients with elevated intraocular pressure (IOP). Methods: Thirty patients with ocular hypertension or early capsular or primary open-angle glaucoma and elevated IOP were randomly assigned to two parallel treatment groups. The treatment period was twenty days. Fifteen patients (Group 1) received latanoprost once daily during the first ten days and, in addition, dorzolamide three times daily during the second ten days. Fifteen patients (Group 2) received dorzolamide three times daily during the first ten days and, in addition latanoprost, once daily during the second ten days. IOP was measured and conjunctival hyperemia was evaluated. Results: In Group 1, the mean IOP on day 0 was 26.8 mmHg; on day 10, 18.7 mmHg; and on day 20, 15.9 mmHg. In Group 2, the mean IOP on day 0 was 26.3 mmHg; on day 10, 21.2 mmHg; and on day 20, 16.1 mmHg. Both groups had clinically significant IOP-lowering effect on day 10 as compared with baseline day (30.2% and 19.4% respectively) (p < 0.01). When dorzolamide was added to latanoprost, the additional IOP reduction was 2.8 mmHg (15%) (p < 0.01) compared with 5.1 mmHg (24.1%) (p < 0.01) when latanoprost was added to dorzolamide. No local serious adverse reactions were observed. A mild but statistically significant increase in conjunctival hyperemia was seen in latanoprost applied patients. Conclusions: The results showed that latanoprost and dorzolamide can be combined successfully to reduce IOP with their additive effects.

引用

页码：37 / 42

页数：5

共 31 条

[1]

Crawford K., Kaufman P.L., Gabelt B.T., Effect of topical PGF2α on aqueous humor dynamics in cynomogus monkeys, Curr Eye Res, 6, pp. 1035-1044, (1987)

[2]

Gabelt B.T., Kaufman P.L., The effect of prostaglandin F2α on trabecular outflow facility in cynomolgus monkeys, Exp Eye Res, 51, pp. 87-91, (1990)

[3]

Wang R.F., Camras C.B., Lee P.Y., Podos S.M., Bito L.Z., Effects of prostaglandis F2α, A2, and their esters in glaucomatous monkey eyes, Invest Ophthalmol Vis Sci, 31, pp. 2466-2470, (1990)

[4]

Bito L.Z., Camras C.B., Gum G.G., Resul B., The ocular hypotensive effects and side effects of prostaglandins on the eyes of experimental animals, Prog Clin Biol Res, 312, pp. 349-368, (1989)

[5]

Hoyng P.F., Groeneboer M.C., The effects of prostacyclin and its stable analog on intraocular pressure, Prog Clin Biol Reg, 312, pp. 369-378, (1989)

[6]

Kerstetter J.R., Brubaker R.F., Wilson S.E., Kullerstrant U., Prostaglandin F2α-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow, Am J Ophthalmol, 105, pp. 30-34, (1988)

[7]

Villumsen J., Alm A., Prostaglandin F2α-isopropylester eye drops: Effect in normal human eyes, Br J Ophthalmol, 73, pp. 419-426, (1989)

[8]

Camras C.B., Siebold E.C., Luntgarten J.S., Serle J.B., Frisch S.C., Podos S.M., Et al., Maintained reduction of intaocular pressure by prostaglandin F2α-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients, Opthalmology, 96, pp. 1329-1336, (1989)

[9]

Guiffre G., The effects of prostaglandin F2 in the human eye, Graefes Arch Clin Exp Ophthalmol, 222, pp. 139-141, (1985)

[10]

Alm A., Villumsen J., PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers, Arch Ophthalmol, 109, pp. 1564-1568, (1991)

← 1 2 3 4 →